2nd treatment: total 8 times, every 2 weeks&gt

2 trials

Sponsors

Kurume University Research Center for Innovative Cancer Therapy, Clinical Research Division, Department of Immunology, Kurume University School of medicine

Conditions

Prostate cancermalignant glioma (glioblastoma)

Phase 2

Phase II clinical trial of personalized peptide vaccination for decetaxel no indicated patients with hormone-refractory prostate cancer

Active, not recruitingJPRN-UMIN000001242

Kurume University Research Center for Innovative Cancer Therapy, Clinical Research DivisionProstate cancer

Start: 2009-04-01Target: 55Updated: 2026-06-29

Phase II clinical trial of personalized peptide vaccination for standard therapy failure patients with malignant glioma (glioblastoma)

Active, not recruitingJPRN-UMIN000001243

Department of Immunology, Kurume University School of medicinemalignant glioma (glioblastoma)

Start: 2009-04-01Target: 40Updated: 2026-06-29